SCHEMBL1687342

SCHEMBL1687342

O=c1[nH]c(O)cc2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.60
GAA P10253 3/20 0.60
LOXL2 Q9Y4K0 1/20 0.56
CDC25B P30305 10/20 0.54
APAF1 O14727 6/20 0.51
CASP3 P42574 5/20 0.51
SENP8 Q96LD8 5/20 0.51
SENP7 Q9BQF6 5/20 0.51
ALDH1A1 P00352 5/20 0.51
SENP6 Q9GZR1 4/20 0.51
HPGD P15428 4/20 0.51
SAE1 Q9UBE0 4/20 0.51
UBA2 Q9UBT2 4/20 0.51
MAPT P10636 3/20 0.51
THRB P10828 3/20 0.51
RECQL P46063 2/20 0.51
UBE2I P63279 2/20 0.51
GALK1 P51570 1/20 0.51
SMAD3 P84022 1/20 0.51
ATG4B Q9Y4P1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6046763 0.76 LOXL2 (0.68) KDM4EGAALOXL2CDC25BAPAF1
SCHEMBL29784203 0.75 KDM4E (0.60) KDM4EGAALOXL2CDC25BAPAF1
SCHEMBL5311576 0.75 KDM4E (0.60) KDM4EGAALOXL2CDC25BAPAF1
SCHEMBL29844316 0.75 LOXL2 (0.61) KDM4EGAALOXL2CDC25BAPAF1
SCHEMBL1818129 0.75 KDM4E (0.60) KDM4EGAALOXL2CDC25BAPAF1
SCHEMBL150458 0.75 KDM4E (0.60) KDM4EGAALOXL2CDC25BAPAF1
SCHEMBL6448568 0.75 KDM4E (0.60) KDM4EGAALOXL2CDC25BAPAF1
SCHEMBL824574 0.75 KDM4E (1.00) KDM4EGAALOXL2CDC25BAPAF1
SCHEMBL1719778 0.75 LOXL2 (0.61) KDM4EGAALOXL2CDC25BAPAF1
SCHEMBL29488099 0.75 KDM4E (1.00) KDM4EGAALOXL2CDC25BAPAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049217-A1 DYED ARTICLES FOR VISIBLE LIGHT FILTERING OAKLEY, INC. (US) 2026-02-19 US disclosed
WO-2017049409-A1 COMPOSITIONS FOR PROMOTING READTHROUGH OF PREMATURE TERMINATION CODONS, AND METHODS OF USING THE SAME THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) 2017-03-30 WO disclosed
US-8822495-B2 Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments SANOFI (FR) 2014-09-02 US disclosed
EP-1987020-B1 AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS SANOFI SA (FR) 2012-10-03 EP disclosed
EP-2066640-B1 2-(1-OXO-1H-ISOQUINOLIN-2-YL) ACETAMIDE DERIVATIVES ORGANON NV (NL) 2011-09-07 EP disclosed
US-7906504-B2 N-tert-Butyl-2-[3-(4-fluoro-3-methoxyphenyl)-1-oxo-7-(3-pyrrolidin-1-ylpropoxy)-1H-isoquinolin-2-yl]acetamide; 2-[3-(3-Chlorophenyl)-7-((S)-2-methyl-3-pyrrolidin-1-ylpropoxy)-1-oxo-1H-isoquinolin-2-yl]-N-isopropylacetamide; antidepressants; hypothalamo-pituitary-adrenal axis modulators N.V. ORGANON (NL) 2011-03-15 US disclosed
US-20090264403-A1 NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS SANOFI-AVENTIS (FR) 2009-10-22 US disclosed
EP-2066640-A2 2-(1-OXO-1H-ISOQUINOLIN-2-YL) ACETAMIDE DERIVATIVES N.V. Organon (NL) 2009-06-10 EP disclosed
EP-1987020-A1 AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS Sanofi-Aventis (FR) 2008-11-05 EP disclosed
WO-2008033757-A2 2-(1-OXO-1H-ISOQUINOLIN-2-YL) ACETAMIDE DERIVATIVES N.V. ORGANON (NL) 2008-03-20 WO disclosed
US-20080064678-A1 2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE DERIVATIVES N.V. ORGANON (NL) 2008-03-13 US disclosed
WO-2007093364-A1 AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS SANOFI-AVENTIS (DE) 2007-08-23 WO disclosed
US-4420308-A Process for the production of reserve effects on polyester textiles and polyester/cellulose mixed fibre textiles: discharge printing with disperse azo dye with alkyl or alkoxy carbonyl, cyand and hydroxy phenyl group CASSELLA AKTIENGESELLSCHAFT (DE) 1983-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049217-A1 DYED ARTICLES FOR VISIBLE LIGHT FILTERING LBR, CRY2, CORO1C KDM4E 3155/4885GAA 4284/4885LOXL2 195/4885
US-20090264403-A1 NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS MCHR1, MRGPRX1, MRGPRX4 KDM4E 463/4885GAA 609/4885LOXL2 4072/4885
US-20080064678-A1 2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE DERIVATIVES SULT2A1, ACAT2, HDAC6 KDM4E 1829/4885GAA 248/4885LOXL2 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.